Restless Leg Syndrome Market Prepares To Move As GSK, UCB Advance Drugs
• By Pharmaceutical Approvals Monthly
UCB could bring the first competitor to GlaxoSmithKline's Requip (ropinirole) for restless leg syndrome to market later this year after submitting an sNDA for Neupro (rotigotine) for RLS
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
